Please login to the form below

Not currently logged in
Email:
Password:

bictegravir

This page shows the latest bictegravir news and features for those working in and with pharma, biotech and healthcare.

ViiV’s two-drug HIV combo backed by CHMP

ViiV’s two-drug HIV combo backed by CHMP

Its main rival is expected to be Gilead’s new fixed-dose regimen Biktarvy, which combines integrase inhibitor bictegravir with the two ingredients in its fast-growing Descovy (emtricitabine/tenofovir alafenamide)

Latest news

  • Gilead says switching studies back new HIV therapy Biktarvy Gilead says switching studies back new HIV therapy Biktarvy

    The results of Study 1844 showed that patients who transferred to treatment with Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) from Triumeq (abacavir/dolutegravir/lamivudine) were able to maintain their viral suppression over

  • Gilead’s triple HIV drug approval prompts GSK lawsuit Gilead’s triple HIV drug approval prompts GSK lawsuit

    Gilead’ s triple HIV drug approval prompts GSK lawsuit. ViiV claims bictegravir infringes its patent estate. ... GSK’s ViiV Healthcare unit has filed a lawsuit against Gilead claiming that its integrase inhibitor bictegravir - which is one of the

  • GSK’s ViiV gets US okay for two-drug HIV regimen GSK’s ViiV gets US okay for two-drug HIV regimen

    that adds integrase inhibitor bictegravir to the two ingredients in its fast-growing Descovy (emtricitabine/tenofovir alafenamide) product.

  • ViiV files two-drug HIV maintenance regimen ViiV files two-drug HIV maintenance regimen

    Gilead has just reported the results of four phase III trials of its three-drug combo of new integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide, showing non-inferiority to

  • Gilead plans fightback against HIV arch-rival ViiV Gilead plans fightback against HIV arch-rival ViiV

    Gilead has reported the results of four phase III trials of a new HIV combination therapy pairing its Descovy product with new candidate bictegravir, and says it is ready to press ... The fixed dose combination of integrase strand inhibitor bictegravir

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics